Table 1.

Oncolytic herpes simplex viruses in completed and ongoing clinical trials for malignant glioma.

Virus (stain)	Country	Year*	Status	Phase	Protocol	Result	References
1716	UK	1996	Closed	I	Intatumoral, 103–105 pfu, single injection	Of 9 patients treated, 4 were alive and well 14–24 months after 1716 administration. No toxicity or serious adverse events.	Trial ID: UK0033** (Rampling et al., 2000)
1716	UK	2000	Closed	I	Intatumoral, 105 pfu, single injection	No toxicity or serious adverse events	(Papanastassiou et al., 2002)
1716	UK	2001	Closed	I	Adjacent brain, 105 pfu, single injection	3 out of 12 patients remained alive and clinically stable at 15–22 months post-surgery and 1716. No toxicity or serious adverse events.	(Harrow et al., 2004)
1716	UK	2006	Open	II/III	Intratumoral	Unpublished	UK0136**
1716	USA	2013	Open	I	Intratumoral/Peritumoral	Unpublished	Trial ID: NCT02031965
G207	USA	1998	Open	I	Intratumoral, 106 – 3 × 109 pfu, single injection	8 out of 21 patients with decreased tumor volume. No toxicity or serious adverse events.	Trial ID: US0235** (Markert et al., 2000)
G207	USA	2002	Closed	Ib	Intratumoral and adjacent brain, total 1.15 × 109 pfu, two injections before and after resection.	Adverse events in 1 of 6 patients.	Trial ID: NCT00028158 (Markert et al., 2009)
G207	USA	2005	Closed	I	Intratumoral injections at 109 pfu, followed by a single focal irradiation (5 Gy) 24 h later.	Marked radiographic response in 3 of 9 patients, with 7.5 months of median survival. No toxicity or serious adverse events.	Trial ID: NCT00157703 (Markert et al., 2014)
G47Δ	Japan	2009	Open	I/II	Stereotactic intratumoral injections, 2nd injection follows 5–14 days later.	Unpublished	Trial No.: UMIN000002661
rQNestin –34.5	USA	2011	Open	I	Peritumoral	Unpublished	Trial ID: US1100**
M032	USA	2014	Open	I	Intratumoral, single injection	Unpublished	Trial ID: NCT02062827

^*Year approved or initiated.

^**According to The Journal of Gene Medicine Clinical Trial site (http://www.abedia.com/wiley/index.html).